Key Takeaways
1. The PRIMA implant is a tiny wireless bionic eye device that helps legally blind patients regain vision, allowing them to read letters and recognize faces.
2. The implant is inserted under the retina in a two-hour surgery and wirelessly connects to augmented-reality glasses with a video camera.
3. The device uses electronics to replace damaged light-sensing cells, sending signals to the brain via surviving retinal cells and the optic nerve.
4. In a clinical trial, over 80% of participants with advanced macular degeneration reported significant vision improvements after receiving the implant.
5. The PRIMA implant represents a breakthrough in treating late-stage macular degeneration and aims for regulatory approval to become available in public health systems.
A tiny wireless bionic eye implant, smaller than a grain of rice, has helped legally blind patients regain enough vision to read letters and recognize faces. This implant, named the PRIMA implant, was created by Science Corporation, a biotech firm from California that focuses on neural engineering.
Surgical Procedure
The device, which measures just 2 millimeters square, is inserted beneath the retina in a surgery that lasts about two hours. After being activated, it wirelessly connects to augmented-reality glasses that have a small video camera. This trial could be a major breakthrough for functional artificial sight.
The system mimics how healthy eyes process visual data but uses electronics to substitute the damaged light-sensing cells. The glasses capture video of the environment and send it to a small processor. This processor uses AI algorithms to turn the image into infrared light patterns, which are then projected onto the implant.
How the Implant Works
The PRIMA chip is fitted with many photodiodes and microelectrodes that change these light patterns into tiny electrical signals. These signals stimulate the surviving retinal cells near the damaged macula, sending information via the optic nerve to the brain. The implant effectively “rewires” around the nonfunctional cells, enabling the brain to reconstruct visual information where it was previously absent.
Since the brain needs to relearn how to understand these new electronic signals, patients must go through months of visual rehabilitation after the implant is activated. The smart glasses have a “zoom-in” function that helps them enlarge text, assisting in early reading tasks.
Clinical Trial Results
In a multicenter clinical trial conducted in the UK, France, Germany, Italy, and the Netherlands, 38 participants with advanced macular degeneration received the device. Prior to surgery, many of them couldn’t read even the largest letters on a vision chart. After a year, over 80% of the patients reported significant improvements, averaging a gain of 25.5 letters, or about five lines, on an eye chart. One participant even improved by 59 letters, which is around 12 lines.
Dr. Mahi Muqit from Moorfields Eye Hospital described the findings as “a new era for artificial vision,” noting that patients “went from being in darkness to being able to start using their vision again.”
Dr. Frank Holz, who authored the paper in the New England Journal of Medicine, stated that the implant “represents a paradigm shift” in treating late-stage macular degeneration, a leading cause of blindness in older adults.
The Bigger Picture
According to the Royal National Institute of Blind People (RNIB), one out of four legally blind individuals in the UK suffers from vision loss due to advanced macular degeneration. Currently, there are no cures available to restore sight after the cells are damaged; treatments can only slow down the disease. The PRIMA implant changes this by providing real central vision restoration, a breakthrough never before seen in human trials.
Max Hodak, co-founder of Science Corporation, referred to the results as “a milestone in neural engineering,” and added, “This breakthrough highlights our commitment to pioneering technologies that offer hope to patients in need.”
The company is now aiming for European regulatory approval, hoping that the device could soon be accessible through public health systems like the NHS. If approved, it would be the first instance where a brain-computer interface designed for vision restoration transitions from experimental research to practical clinical use, turning the dream of artificial sight into a reality.
Leave a Reply